Previous 10 | Next 10 |
home / stock / cyccp / cyccp news
BERKELEY HEIGHTS, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced it will present preliminary dose esc...
BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in...
- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 – - Demonstrated evidence of target engagement for CDK2 and CDK9 – - Company to host R&D day in ...
BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2022 financial results ...
- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors - - No Dose Limiting Toxicities Observed at All Dose Levels Enrolled to Date - - Demonstrated Evidence of Target Engagement for CDK2 and CDK9 - - Early Anticancer Activity...
BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M....
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2022 Earnings Conference Call May 11, 2022, 16:30 ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President, CEO & Executive Director Paul McBarron - EVP, CFO, COO, Secretary & Executive Director Mark Kirschbaum - SVP ...
- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC140 for Treatment of Advanced Solid Tumors and Lymphomas - - Publicat...
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2022 financial results on...
BERKELEY HEIGHTS, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Compan...
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock Company Name:
CYCCP Stock Symbol:
NASDAQ Market:
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 37.2% to $0.7466 on volume of 94,759,512 shares GameStop Corporation (GME) rose 0.0% to $46.5702 on volume of 64,189,668 shares Trinity Place Holdings Inc. (TPHS) rose 126.9% to $0....